Skip to main content
Equibles
BSX logo

BSX · Boston Scientific Corp

Track BSX — free

Use BSX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about BSX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$48.17 -1.69 (-3.39%) At close · Aug 26
Market Cap
$72.26B
Shares
1.45B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$48.17 Open$47.00 Day$46.90–48.54 52W close$42.63–108.14 Avg vol 30d20.6M Short int27.6M · 1.9% float · 1.6d Short vol36% Last earningsOct 28, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 3

Up next

Next earnings call
Oct 28, 2026 Scheduled · in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 3, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Sell Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High
      Market backdrop VIX 15.2 · calm Equity put/call 0.64
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −30%
      below
      Price vs 50-day avg +4%
      above
      RSI (14) 47
      neutral
      MACD trend Negative
      52-week position 8%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +5%
      trailing
      6-month return −34%
      trailing
      YTD return −49%
      this year
      Relative strength −46%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $47 › 200d $69 — 200d above 50d
      Institutional flow Distributing
      -12% holders QoQ · +149 funds added
      Insider flow Accumulating
      Net +$9.5M over 90 days · 0% sells
      Short interest Rising
      1.91% of float · ▲ +24.0% MoM · 1.6 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      1,476 holders — mid 3-yr range
      Squeeze score 53
      elevated · 0–100
      Fundamentals
      Excellent
      Revenue growth +12%
      Y/Y
      Gross margin 153%
      expanding
      EPS growth +55%
      Y/Y
      Free cash flow $3.7B
      Valuation P/E 20.2
      below peers
      Buyback $3.0B
      remaining
      Balance sheet $9.5B
      net debt
      Quant / Vol
      risk profile
      High
      Volatility 37%
      annualized · 1-yr
      Max drawdown −61%
      past year
      ATR 3.8%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 2 of last 3
      Latest guidance · from the 8-K filed Jul 29, 2026
      full year 2026
      Reported net sales growth Initiated 5.5% – 6.5%
      Organic net sales growth Initiated 5% – 6%
      Adjusted EPS, excluding certain charges (credits) Non-GAAP Initiated $3.28 – $3.32
      third quarter of 2026
      Organic net sales growth Initiated 3% – 5%
      Reported net sales growth Initiated 3% – 5%
      Adjusted EPS, excluding certain charges (credits) Non-GAAP Initiated $0.80 – $0.82
      Prior guidance period ended · from the 8-K filed Apr 22, 2026
      Net sales growth on a reported basis · second quarter of 2026 5.5% – 7.5%
      Net sales growth on an organic basis · second quarter of 2026 5% – 7%
      Adjusted EPS, excluding certain charges (credits) · second quarter of 2026 $0.82 – $0.84
      Guided vs delivered · last 3 settled
      GAAP EPS full year 2025
      guided $1.97 – $2.01
      $1.94 Miss −2.5%
      GAAP EPS Third Quarter 2025
      guided $0.44 – $0.46
      $0.51 Beat +13.3%
      GAAP EPS second quarter of 2025
      guided $0.45 – $0.47
      $0.53 Beat +15.2%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −30% Bearish
      Price vs 50-day avg
      +4% Bullish
      RSI (14)
      47 Neutral
      MACD trend
      Negative Bearish
      52-week position
      8% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $47 › 200d $69 — 200d above 50d
      Institutional flow Distributing
      -12% holders QoQ · +149 funds added
      Insider flow Accumulating
      Net +$9.5M over 90 days · 0% sells
      Short interest Rising
      1.91% of float · ▲ +24.0% MoM · 1.6 days cover
      Volume signal Reversal watch
      High volume on a down day — possible exhaustion
      Institution breadth Steady
      1,476 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $43 Now $48 · 8% Range high $108
      vs 200-day avg -30% vs 50-day avg +4%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EPS non-GAAP $0.86 Q2 2026 —
      APAC operational net sales growth non-GAAP 11.2% Q2 2026 —
      APAC reported net sales growth 11.2% Q2 2026 —
      Cardiovascular operational net sales growth non-GAAP 7.8% Q2 2026 —
      Cardiovascular reported net sales growth 8.3% Q2 2026 —
      EMEA operational net sales growth non-GAAP 4.2% Q2 2026 —
      EMEA reported net sales growth 6.1% Q2 2026 —
      LACA operational net sales growth non-GAAP 16.2% Q2 2026 —
      LACA reported net sales growth 22.4% Q2 2026 —
      MedSurg operational net sales growth non-GAAP 5.4% Q2 2026 —
      MedSurg reported net sales growth 5.9% Q2 2026 —
      Operational net sales growth non-GAAP 7% Q2 2026 —
      Reported net sales growth 7.5% Q2 2026 —
      U.S. operational net sales growth non-GAAP 6.2% Q2 2026 —
      U.S. reported net sales growth 6.2% Q2 2026 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      BSX
      Boston Scientific Corp
      this stock
      		$72.26B -49.5% +12.5% 20.2 1.9%
      ABT
      Abbott Laboratories
      		 $203.22B -8.9% +5.7% 32.7 1.2%
      SYK
      Stryker Corp
      		 $126.45B -6.2% +11.2% 34.2 1.8%
      MDT
      Medtronic plc
      		 $117.57B -4.2% +8.4% 24.6 1.1%
      EW
      Edwards Lifesciences Corp
      		 $52.38B +6.5% +11.5% 52.2 1.8%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,476
      % held
      95.6%
      Net QoQ
      +13.8M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      1,092
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      27.6M
      Days to cover
      1.6d
      Change
      +5.3M sh
      View
      Short Volume
      Short vol %
      36%
      As of
      Aug 26, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      11.7K
      Value
      $538.0K
      As of
      Jul 29, 2026
      View
      Off-Exchange
      Off-exchange %
      55.3%
      Week of
      Jul 20, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Cluster buy
      Net (90d)
      +$9.5M
      Buyers / Sellers
      4 / 0
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Gilbert Cisneros
      Amount
      $1.0K–$15.0K
      Traded
      Jun 5, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $20.1B
      EPS diluted
      $1.94
      View
      Buybacks
      Authorized
      $5.0B
      Remaining
      $3.0B
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 26, 2026
      This year
      19
      View
      Proposed Sales
      Value
      $15.0M
      Shares
      160.9K
      Filed
      Feb 2, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Sep 10, 2026
      Last call
      Jul 29, 2026
      View
      Investor Relations
      Upcoming events
      2
      View

      Performance

      5D 20D 120D MTD YTD
      BSX -7.4% +4.6% -34.0% +3.1% -49.5%
      SPY -0.4% +5.0% +12.4% +2.6% +12.3%
      vs SPY -7.0% -0.4% -46.4% +0.5% -61.8%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $5.00B
      Spent (derived)
      $2.00B
      Remaining
      $3.00B
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 885725 CUSIP 101137107 13F (30d) 1139 filings 1103 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)